NASDAQ : NGNE
Neurogene Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 28.82 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 576.73M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 551.31M |
| Enterprise Value | 334.27M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 20.01M |
| Shares Outstanding | 20.01M |
| Shares Change (YoY) | +12.28% |
| Shares Change (QoQ) | +1.10% |
| Owned by Insiders (%) | 7.01% |
| Owned by Institutions (%) | 61.00% |
| Float | 11.30M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.01 |
| P/TBV Ratio | 2.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.64 |
| Quick Ratio | 10.50 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -40,409.00 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -45.32% |
| Return on Assets (ROA) | -27.97% |
| Return on Invested Capital (ROIC) | -29.73% |
| Return on Capital Employed (ROCE) | -54.40% |
| Weighted Average Cost of Capital (WACC) | 15.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$848,168 |
| Employee Count | 131 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.09 |
| 52-Week Price Change | -15.67% |
| 50-Day Moving Average | 30.74 |
| 200-Day Moving Average | 27.82 |
| Relative Strength Index (RSI) | 50.98 |
| Average Volume (20 Days) | 356,024 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.09M |
| Short Previous Month | 4.97M |
| Short % of Shares Out | 25.45% |
| Short % of Float | 45.08% |
| Short Ratio (days to cover) | 13.31 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -88.38M |
| Operating Income | -121.23M |
| Pretax Income | -111.11M |
| Net Income | -111.11M |
| EBITDA | -117.99M |
| EBIT | -121.23M |
| Earnings Per Share (EPS) | -$5.04 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 225.39M |
| Total Debt | 8.35M |
| Net Cash | 217.05M |
| Net Cash Per Share | $10.85 |
| Equity (Book Value) | 217.13M |
| Book Value Per Share | 13.72 |
| Working Capital | 207.41M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -86.82M |
| Capital Expenditures | -890,000 |
| Depreciation & Amortization | 3.24M |
| Net Borrowing | -43,000 |
| Free Cash Flow | -87.71M |
| FCF Per Share | -$4.38 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -12.28% |
| Shareholder Yield | -12.28% |
| Earnings Yield | -18.31% |
| FCF Yield | -15.91% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $77.88 |
| Price Target Difference | 182.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |